Ixabepilone - CAS 219989-84-1
Catalog number: B0084-063099
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Ixabepilone (also known as azaepothilone B, or BMS-247550) is an orally bioavailable microtubule inhibitor. Ixabepilone was a semisynthetic analogue of epothilone B with antineoplastic activity. Ixabepilone binds to tubulin and promotes tubulin polymerization and microtubule stabilization, thereby arresting cells in the G2-M phase of the cell cycle and inducing tumor cell apoptosis. This agent demonstrates antineoplastic activity against taxane-resistant cell lines. Ixabepilone was approved in 2007.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-063099 5 mg $198 In stock
Bulk Inquiry
Publictions citing BOC Sciences Products
  • >> More
Azaepothilone B; BMS 247550; BMS 247550-1; Ixempra
1.Mechanism of action of ixabepilone and its interactions with the βIII‑tubulin isotype
Manu Lopus • Greg Smiyun • Herb Miller • Emin Oroudjev • Leslie Wilson • Mary Ann Jordan. Cancer Chemother Pharmacol (2015) 76:1013–1024
Here we examined ixabepilone’s binding to microtubules and its effects on microtubule assembly in vitro and on the parameters of microtubule dynamic instability both in vitro with microtubules assembled from puriied tubulin and with microtubules in MCF7 breast cancer cells. We found that ixabepilone binds to microtubules with a variable stoichiometry of 1–2 molecules of drug for every tubulin molecule in microtubules. The absence or reduction of βIII-tubulin makes microtubules more susceptible to the suppressive effects of ixabepilone on dynamic instability in vitro and in cells and enhances mitotic arrest. Our results indicate that βIII-tubulin reduces the effects of ixabepilone on microtubule dynamics and on mitotic arrest, and thus increased βIII-tubulin expression may contribute to ixabepilone resistance in tumors.
2.Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer
Neelima Denduluri • James J. Lee • Janice Walshe • Arlene W. Berman • Ujala Vatas • Catherine K. Chow. Invest New Drugs (2006) 25:63–67
Finally, this trial was designed to rule out a 5% response rate in favor of a 20%response rate using a two stage design. With only 12 patients enrolled and no responses, there is a 90% chance that the true response rate is 17.5% or less. Given the number of other positive trials with this agent, it is possible that the current trial has produced a false negative result, although it is unlikely that the true response ratewould be 20% or higher. Unlike previous trials with efficacy of ixabepilone in breast cancer with different dosing schedules, our trial suggests that the 8–10 mg/m2 daily for 3 days regimen may not be an effective therapy in this heavily pretreated population. Current Phase III trials with ixabepilone should give us more definitive conclusions about the therapeutic efficacy of different dose schedules of ixabepilone in metastatic breast cancer.
3.Weekly ixabepilone administration in heavily pretreated metastatic breast cancer patients
Ellen B. Kossoff • Nuttapong Ngamphaiboon • Thomas J. Laudico • Tracey L. O’Connor. Med Oncol (2011) 28:S115–S120
Weekly paclitaxel is regarded as a standard of care in metastatic breast cancer due to improvements in efficacy and tolerability seen with this schedule. The Cancer and Leukemia Group B (CALGB 9840) demonstrated that weekly paclitaxel was superior to every 3-week paclitaxel as treatment of metastatic breast cancer with improvements seen in RR (42%vs. 29%) and TTP (median, 9 vs. 5 months) with this schedule. Because ixabepilone is pharmacologically similar to the taxanes, weekly administration of ixabepilone may offer similar benefits to those of weekly paclitaxel. The available clinical data,while limited, suggest that weekly ixabepilone is a reasonable option for breast cancer patients.
4.Silencing A7-nAChR levels increases the sensitivity of gastric cancer cells to ixabepilone treatment
Chao-Chiang Tu & Chien-Yu Huang & Wan-Li Cheng & Chin-Sheng Hung. Tumor Biol.
Taxanes are potent antimicrotubule agents that are used in the treatment of advanced gastric cancer as first- and second-line therapies and that have response rates of approximately 15∼24%. However, the majority of patients with advanced gastric cancer eventually develop progressive diseases after initially responding to taxane-based treatment. Ixabepilone, a semisynthetic analog of epothilone B, promotes tumor cell death by stabilizing microtubules and inducing apoptosis similar to taxanes. In fact, ixabepilone structurally differs from taxanes and is less susceptible to tumor resistance mechanisms, including P-glycoprotein overexpression and beta-tubulin mutations, the two most common mechanisms of resistance to paclitaxel. In addition, ixabepilone is more potent than paclitaxel in promoting beta-tubulin polymerization in both paclitaxel-sensitive and paclitaxel-resistant cell lines. Accumulating clinical trials have proven the efficacy of ixabepilone in a broad variety of tumor types, including metastatic or treatment-resistant breast cancer, advanced prostate cancer, pancreatic cancer, non-small cell lung cancer, endometrial carcinoma, ovarian cancer, and renal cell carcinoma. The US Food and Drug Administration has approved ixabepilone for the treatment of locally advanced breast cancer since 2007. Trials examining ixabepilone as a monotherapy or in combination with other classical cytotoxics are currently in progress, and further roles for ixabepilone in the treatment of cancer are hoped for
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Microtubule/Tubulin Products

CAS 141430-65-1 ABT 751

ABT 751
(CAS: 141430-65-1)

ABT 751, also called E7010, is a a novel bioavailable tubulin-binding and antimitotic agent (in neuroblastoma: IC50= 0.6–2.6 μM; in non-neuroblastoma cell line...

CAS 61-73-4 Methylene Blue

Methylene Blue
(CAS: 61-73-4)

Methylene Blue, whose brand name is Calbiochem, inhibits tau filament formation (IC50 = 1.9 μM) and soluble guanylyl cyclase.

CAS 33069-62-4 Taxol

(CAS: 33069-62-4)

Taxol, also called Paclitaxel, derived from the bark of the Pacific yew tree, has a broad antineoplastic spectrum uused in cancer chemotherapy.It promotes and s...

CAS 917369-31-4 MPC 6827 hydrochloride

MPC 6827 hydrochloride
(CAS: 917369-31-4)

MPC 6827 hydrochloride, the hydrochloride salt form of verubulin, inhibits of microtubule formation (IC50 = 1.5 - 3.4 nM). in vitro: inhibits polymerization of...

CAS 912-60-7 Noscapine hydrochloride

Noscapine hydrochloride
(CAS: 912-60-7)

Noscapine hydrochloride, the hydrochloride salt form of Noscapine which binds to tubulin and arrests mammalian cells in mitosis at a concentration of 20 µM . No...

(CAS: 1169755-45-6)

INDY,under the IUPAC name 1-(3-ethyl-5-hydroxy-1,3-benzothiazol-2-ylidene)propan-2-one, is a DYRK1A/B inhibitor (DYRK1B: IC50= 0.23μM; DYRKA: IC50= 0.230.24μM)....

(CAS: 354759-10-7)

PBOX-15 is a novel microtubule inhibitor, which induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cel...

C2N 8E12

C2N 8E12 is a humanized antibody that currently in clinical development works to protect against Alzheimer’s disease by stimulating the immune system to activat...


AADvac-1 is an active vaccine designed to raise antibodies against pathological tau protein (the primary constituent of neurofibrillary pathology in AD). These ...

CAS 1402727-29-0 PE859

(CAS: 1402727-29-0)

PE859 is a potent dual inhibitor of tau and Aβ aggregation with IC50 values of 0.66 and 1.2 μM, respectively.

CAS 64-86-8 Colchicine

(CAS: 64-86-8)

Colchicine, a toxic plant-derived alkaloid extracted from plants of the genus Colchicum, inhibits microtubule polymerization (IC50 = 3.2 μM).

CAS 714272-27-2 Plinabulin

(CAS: 714272-27-2)

Plinabulin is a vascular disrupting agent (VDA) against tubulin-depolymerizing with IC50 value of 9.8~18 nM in tumor cells under the development of Nereus Pharm...

CAS 90332-66-4 7-xylosyltaxol

(CAS: 90332-66-4)

7-xylosyltaxol is a taxol (Paclitaxel) derivative, which binds to tubulin and inhibits the disassembly of microtubules.

CAS 71486-22-1 Vinorelbine

(CAS: 71486-22-1)

Vinorelbine, also called Navelbine, a 5′NOR semisynthetic vinca alkaloid which arrests tumor cell growth in metaphase by binding to tubulin and preventing form...

CAS 917111-44-5 Lexibulin

(CAS: 917111-44-5)

lexibulin, also known as CYT997,  is an orally bioavailable small-molecule with tubulin-inhibiting, vascular-disrupting, and potential antineoplastic activ...

CAS 474645-27-7 MMAE

(CAS: 474645-27-7)

MMAE, whose full name is Monomethyl auristatin E, inhibits tubulin polymerization so that it inhibits cell division.

CAS 1201898-17-0 Vinflunine Tartrate

Vinflunine Tartrate
(CAS: 1201898-17-0)

Vinflunine induces apoptosis in neuroblastoma SK-N-SH cells through a postmitotic G1 arrest and a mitochondrial pathway in a concentration-dependent manner with...

CAS 110417-88-4 Dolastatin 10

Dolastatin 10
(CAS: 110417-88-4)

Dolastatin 10 is an inhibitior of microtubule disassembly (IC50= 1.2μM) and potently inhibits vincristine binding to tubulin in a noncompetitive manner ( Ki= 1....

CAS 2068-78-2 Vincristine

(CAS: 2068-78-2)

Vincristine is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM.

Chemical Structure

CAS 219989-84-1 Ixabepilone

Quick Inquiry

Verification code

Featured Items